Drugs in Dev. Gastroenterology
Phase II/ Phase III
Lead Product(s) : HIL-214
Therapeutic Area : Gastroenterology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
HilleVax’s Norovirus Vaccine Fails Phase 2 Trial, Stock Falls 80%
Details : HIL-214, an investigational IM vaccine for norovirus-related gastroenteritis, did not meet its primary endpoint in the NEST-IN1 trial. The company will stop its development in infants aged 5 months.
Product Name : HIL-214
Product Type : Vaccine
Upfront Cash : Inapplicable
August 07, 2024
Lead Product(s) : HIL-214
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clonidine
Therapeutic Area : Gastroenterology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Monopar Announces Timeline of Upcoming Data Events for Validive, Camsirubicin, and MNPR-202
Details : Validive® (clonidine hydrochloride) is a novel mucobuccal tablet (MBT) formulation of clonidine. The mucobuccal tablet provides for prolonged local delivery of clonidine to the regions of oral mucosal radiation damage in oropharyngeal cancer (OPC) patie...
Product Name : Validive
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 27, 2022
Lead Product(s) : Clonidine
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clonidine
Therapeutic Area : Gastroenterology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Monopar Expands Phase 2b/3 VOICE Clinical Trial to Europe
Details : The trial, which began earlier this year in the US, is evaluating Validive® (clonidine HCl MBT) to prevent the onset of severe oral mucositis (SOM) in oropharyngeal cancer (OPC) patients treated with chemoradiotherapy.
Product Name : Validive
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 13, 2021
Lead Product(s) : Clonidine
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clonidine
Therapeutic Area : Gastroenterology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : This analysis provided the rationale for the design of Monopar’s Phase 2b/3 VOICE trial, which is open and accruing oropharyngeal cancer patients in the US.
Product Name : Validive
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 24, 2021
Lead Product(s) : Clonidine
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clonidine
Therapeutic Area : Gastroenterology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Monopar Reaches Target Number of Clinical Sites in Phase 2b Portion of 2b/3 Validive® VOICE Trial
Details : The VOICE study evaluates Validive® for the prevention of severe oral mucositis (SOM) in oropharyngeal cancer patients. SOM results from the chemoradiation used to treat oropharyngeal cancer (OPC).
Product Name : Validive
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 08, 2021
Lead Product(s) : Clonidine
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clonidine
Therapeutic Area : Gastroenterology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Patent provide claims covering “Clonidine and/or clonidine derivatives for use in the prevention and/or treatment of adverse side effects of chemotherapy”.
Product Name : Validive
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 11, 2020
Lead Product(s) : Clonidine
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Galacto-Oligosaccharide
Therapeutic Area : Gastroenterology
Study Phase : Phase II/ Phase III
Sponsor : Qualigen Therapeutics
Deal Size : Undisclosed
Deal Type : Merger
Ritter Pharmaceuticals, Inc. and Qualigen, Inc. Announce Merger Agreement
Details : The merged company will focus on the development of Qualigen’s nanotechnology therapies for the treatment of cancer and infectious diseases, while also continuing to operate its profitable diagnostic business.
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
January 21, 2020
Lead Product(s) : Galacto-Oligosaccharide
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II/ Phase III
Sponsor : Qualigen Therapeutics
Deal Size : Undisclosed
Deal Type : Merger
Reset All
